RATIO-SALBUTAMOL SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

SALBUTAMOL (SALBUTAMOL SULFATE)

제공처:

TEVA CANADA LIMITED

ATC 코드:

R03AC02

INN (국제 이름):

SALBUTAMOL

복용량:

0.5MG

약제 형태:

SOLUTION

구성:

SALBUTAMOL (SALBUTAMOL SULFATE) 0.5MG

관리 경로:

INHALATION

패키지 단위:

2.5ML

처방전 유형:

Prescription

치료 영역:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

제품 요약:

Active ingredient group (AIG) number: 0108887009; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2019-07-09

제품 특성 요약

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate nebules P.F. 1.25MG/2.5 ML, 5.0 MG/2.5 ML AMPOULES
Bronchodilator
(beta
2
-adrenergic stimulant)
TEVA CANADA LIMITED..
30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA, M1B 2K9
Control: 165512
DATE OF PREPARATION:
JULY 3, 2013
Teva Canada Limited.
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
7
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................